NeoTherapeutics, Inc. (NEOT) - 500 Beiträge pro Seite

[benefactor [KommA]]

NeoTherapeutics Presents Positive Effects of Neotrofin(TM) In Parkinson`s Disease Model at the World Congress of Pharmacology
Updated: Tuesday, July 9, 2002 08:50 AM ET Printer-friendly version

IRVINE, Calif., July 9 /PRNewswire-FirstCall/ -- NeoTherapeutics, Inc. (Nasdaq: NEOT, news, msgs) presented exciting new data today from two studies on the acute and neuroprotective effects of Neotrofin(TM) in animal models of Parkinson`s disease at the XIVth World Congress of Pharmacology in San Francisco. In the pre-clinical studies, the data demonstrated that Neotrofin caused an acute improvement in motor function in rats. These pre-clinical studies support the recently reported positive preliminary clinical results from a human phase 2 study of Neotrofin in patients with early stages of Parkinson`s disease.

"The acute treatment studies demonstrated that in addition to being neuroprotective in Parkinson`s disease, Neotrofin may modulate dopaminergic activity, resulting in acute positive clinical efficacy," stated David R. Helton, Director of Behavioral Pharmacology and Toxicology at NeoTherapeutics. "Neotrofin protected dopamine neurons both in animal models of Parkinson`s disease and in tissue culture. Dopamine neurons degenerate in patients with Parkinson`s disease, and the models used in these experiments are commonly used to evaluate drugs for the treatment of Parkinson`s disease."

"These studies represent strong evidence of Neotrofin`s potential as a treatment for Parkinson`s disease," said Alvin J. Glasky, Ph.D., CEO and Chief Scientific Officer of NeoTherapeutics. "Both the acute and neuroprotective effects of Neotrofin in these models provide the rationale for the continued clinical development of this drug in Parkinson`s disease."

The phase 2 study of Neotrofin in Parkinson`s disease was recently completed and preliminary results demonstrated a statistically significant acute effect on motor function for up to two weeks of treatment. A follow-up study for Neotrofin in Parkinson`s disease is under development and will be conducted pending available financial resources.

Parkinson`s disease is one of the major neurodegenerative disorders affecting more than one million patients in North America alone. The principal hallmarks of Parkinson`s disease are slowness of movement, rigidity and tremor. Although current treatments provide some symptomatic relief, Parkinson`s disease progresses inexorably, often over 10 to 20 years, to severe immobility and a bedridden state.

NeoTherapeutics seeks to create value for stockholders through the discovery and out-licensing of drugs for central nervous system disorders, the in-licensing and commercialization of anti-cancer drugs, and the out-licensing of new drug targets discovered through genomics research. Neotrofin(TM) is in clinical development in Parkinson`s disease, spinal cord injury and chemotherapy-induced neuropathy. The Company`s lead oncology drug, satraplatin, is being prepared for a phase 3 study in prostate cancer. Additional anti-cancer drugs are in phase 1 and 2 human clinical trials, and the Company has a rich pipeline of pre-clinical neurological drug candidates. For additional information visit the Company`s web site at www.neot.com .

[mirflltkeinnameein]

Hmm, kann jemand was über diesen Wert sagen ? Die Umsätze in US sind ja gar nicht sooo übel (7.301.400 Stücker heute). Hier in Deutschland scheint allerdings nicht viel zu passieren. 52-Wochen Range ist zwischen 0.14 und 4.90, durchschnittliches Handelsvolumen 1.300.000 Stück. Haben wir heute Gewinnmitnahmen gesehen oder was ist da los ?

Gruß
mfkne

[benefactor [KommA]]